
TXMD
Therapeuticsmd
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About TXMD
Therapeuticsmd, Inc.
A company that develops branded prescription, generic prescription and over-the-counter produts for women
951 Yamato Road, Suite 220, Boca Raton, Florida 33431
--
Therapeuticsmd, Inc., was incorporated in Utah in 1907 as Croff Mining Company, subsequently renamed Croff Oil Company in 1952 and Croff Enterprises, Inc., in 1996. Is a women's healthcare products company focused on creating and commercializing products specifically for women. The company currently manufactures and distributes branded and generic prescription prenatal vitamins as well as over-the-counter, or OTC, vitamins and cosmetics. The company is currently focused on conducting clinical trials required for regulatory approval and commercialization of advanced hormone therapies (HT), drug products designed to relieve symptoms and reduce health risks associated with menopause-related hormone deficiency, including hot flashes, osteoporosis and vaginal dryness. The company is developing these proposed hormone therapy products, which contain estradiol and progesterone alone or in combination, with the aim of providing equivalent efficacy at lower doses, thereby enhancing side effect characteristics compared to competing products. Therapeuticsmd, Inc., has received acceptance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to conduct clinical trials on three proposed products and intends to commence clinical trials on two of them.
Company Financials
EPS
TXMD has released its 2025 Q1 earnings. EPS was reported at -0.06, versus the expected 0, missing expectations. The chart below visualizes how TXMD has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
TXMD has released its 2025 Q1 earnings report, with revenue of 393.00K, reflecting a YoY change of 25.56%, and net profit of -653.00K, showing a YoY change of 11.04%. The Sankey diagram below clearly presents TXMD's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available